[Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Maze Therapeutics director Nancy C. Andrews was granted a stock option on 09/22/2025 to buy 18,000 shares of Maze Therapeutics, Inc. (MAZE) common stock at an exercise price of $23.67 per share. The option award appears in a Form 4 filed on 09/24/2025 and is reported as a direct beneficial holding of 18,000 underlying shares after the transaction. The disclosure states the option will vest in nine equal monthly tranches (1/9 each month) with the first tranche vesting on October 1, 2025, subject to continued service. The instrument lists a date of exercisability/expiration of 09/21/2035 and zero listed cash paid on exercise in the table.

Positive

• Director awarded equity: Option to acquire 18,000 shares at $23.67 recorded on Form 4
• Clear vesting schedule disclosed: Vests 1/9 monthly with first tranche on October 1, 2025

Negative

• Long dated exercisability/expiration entry: Listed as 09/21/2035 in the table which may affect timing assumptions
• Limited disclosure of plan context: Filing does not provide grant fair value, plan name, or impact on outstanding shares

Insights

Securities Analyst

TL;DR: Director received a time‑based stock option for 18,000 shares at $23.67, vesting monthly beginning Oct 1, 2025; reported on Form 4.

The grant is a standard director equity award disclosed on a Form 4 and creates direct beneficial ownership of 18,000 underlying shares post‑transaction. The award vests in nine monthly tranches beginning October 1, 2025, which ties realization to continued service. The listed exercise price of $23.67 and the long dated exercisability/expiration entry (09/21/2035) are key contract terms investors will note when modeling potential dilution and future share issuance timing. This is a routine corporate governance disclosure without additional compensatory or financing details in the filing.

Corporate Governance Expert

TL;DR: This is a routine director option grant with time‑based vesting; materiality is limited to standard equity compensation disclosure.

The Form 4 shows a single, non‑derivative beneficial ownership event tied to an option award exercisable into 18,000 common shares. The vesting schedule—1/9 monthly with first vesting on October 1, 2025—indicates short, service‑based vesting rather than performance hurdles. The filing supplies the primary contract terms but does not include grant date fair value, plan reference, or any change to outstanding share counts, limiting further governance or accounting assessment from this document alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Andrews Nancy C

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.67	09/22/2025		A		18,000		(1)	09/21/2035	Common Stock	18,000	$0	18,000	D

Explanation of Responses:

1. The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Nancy C. Andrews report on Form 4 for MAZE?

Answer: A stock option grant dated 09/22/2025 to acquire 18,000 shares of MAZE common stock at an exercise price of $23.67, reported on Form 4 filed 09/24/2025.

How does the option vest and when does vesting begin?

Answer: The option vests in nine equal monthly tranches (1/9 each month) with the first tranche vesting on October 1, 2025, subject to continued service.

What is the exercise price and number of underlying shares?

Answer: The exercise price is $23.67 and the option covers 18,000 underlying shares of common stock.

Is the reported ownership direct or indirect?

Answer: The Form 4 reports the ownership as direct (D) and shows 18,000 shares beneficially owned following the transaction.

Does the filing state when the option can be exercised or expires?

Answer: The table lists a date of exercisability/expiration as 09/21/2035 in the derivative securities section.